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Abstract
Background: Tobacco smoking remains the leading modifiable health hazard and varenicline is amongst the most
popular pharmacological options for smoking cessation. The purpose of this study is to critically evaluate the
extent of gastrointestinal adverse effects of varenicline when used at maintenance dose (1 mg twice a day) for
smoking cessation.
Methods: We conducted a meta-analysis of randomised controlled trials published in PUBMED and EMBASE
according to the PRISMA guidelines. Selected studies satisfied the following criteria: (i) duration of at least 6 weeks,
(ii) titrated dose of varenicline for 7 days then a maintenance dose of 1 mg twice-per-day, (iii) randomized
placebo-controlled design, (iv) extractable data on adverse event - nausea, constipation or flatulence. Data was
synthesized into pooled odd ratios (OR) basing on random effects model. Quality of studies was also rated as per
Cochrane risk-of-bias assessment. Number need to harm (NNH) was calculated for each adverse effect.
Results: 98 potentially relevant studies were identified, 12 of which met the final inclusion criteria (n = 5114). All
12 studies reported adverse events on nausea, which led to an OR of 4.45 (95% CI = 3.79-5.23, p < 0.001; I
2 =
0.06%, CI = 0%-58.34%) and a NNH of 5. Eight studies (n = 3539) contain data on constipation pooled into an OR
of 2.45 (95% CI = 1.61-3.72, p < 0.001; I
2 = 34.09%, CI = 0%-70.81%) with a NNH of 24. Finally, five studies (n =
2516) reported adverse events of flatulence, which pooled an OR of 1.74 (95% CI = 1.23-2.48, p = 0.002; I
2 = 0%,
CI = 0%- 79.2%) with a NNH of 35.
Conclusions: Use of varenicline at maintenance dose of 1 mg twice a day for longer than 6 weeks is associated with
adverse gastrointestinal effects. In realistic terms, for every 5 treated subjects, there will be an event of nausea, and
for every 24 and 35 treated subjects, we will expect an event of constipation and flatulence respectively. Family
physicians should counsel patients of such risks accordingly during their maintenance therapy with varenicline.
Background
Tobacco smoking remains the most modifiable risk
factor for premature death and all-cause mortality [1],
with a global estimate of 4.83 million attributable deaths
in year 2000 [2]. As a result, many pharmacological
agents have been developed to help patients stop tobacco
smoking, some of which can be administered either
nasally, orally (chewable gum or tablets) or topically (e.g.,
nicotine replacement patch). Amongst these agents, vare-
nicline (branded as Champix
© in UK and Canada, Chan-
tix
© in USA) has been shown to be the one of the most
effective oral pharmacological agents for continued
abstinence. Varenicline acts as a partial a4b2 nicotinic
acetylcholine receptor agonist in the brain to potentially
decrease the degree of cravings and withdrawal symp-
toms during the period of smoking cessation, with effects
superior to both placebos and other pharmacological
agents [3]. Animal studies have found that tobacco addic-
tion is mediated via nicotinic acetylcholine receptors
(nAChRs) in the meso-limbic area of the brain that con-
tain a4 and b2 subunits. While a4 subunits are needed
for sensitization and reinforcement to nicotinic effects
and their tolerance, involvement of b2 subunits are indis-
pensable for development of dependence [4]. In vivo stu-
dies have shown that in the presence of nicotine,
varenicline acts as a partial agonist which stimulates the
release of dopamine (to ameliorate the symptoms of crav-
ing and withdrawal) and simultaneously block the
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dence)[5,6]. When compared to other mainstream phar-
macotherapies (e.g., nicotine replacement therapy and
bupropion), varenicline remains as the most effective
choice for smoking cessation [7] and is validated by high-
quality meta-analysis [8]. Nevertheless, varenicline has
been associated with adverse events like headache, fati-
gue, sleep disorder, nausea and constipation [9,10].
Whilst risks of neuropsychiatric adverse events due to
varenicline have already been reported in a polled analy-
sis [11], the likelihood of major gastrointestinal adverse
effects (such as nausea, constipation and flatulence) dur-
ing maintenance phase lacks precise documentation. We
hereby performed a meta-analysis of randomized double-
blinded placebo-controlled trials to critically examine the
relative risks of nausea, constipation and flatulence due
to maintenance dose of varenicline (1 mg twice a day for
at least 6 weeks) in the context of smoking cessation.
Methods
Eligibility criteria
Our primary interest was the reported gastrointestinal
adverse-effects in using varenicline at the indicated
maintenance dose (1 mg) for duration longer than six
weeks. To minimise heterogeneity, we limited our scope
to double-blind randomised placebo-controlled trials
with comparable sample sizes and a satisfactory score
from the Cochrane risk of bias assessment tool
described by Higgins [12]. Eligible studies must use a
one-week titrated dose (0.5 mg) of varenicline prior to
maintenance dose (1 mg twice a day), and contain at
least one extractable adverse gastrointestinal event of
nausea, constipation or flatulence.
Search strategy
A literature search of published medical reports was
performed in all languages from PUBMED (from 1947
to December 2010), EMBASE (from 1947 to December
2010) and All EBM Reviews using the OVID Portal of
Queen’sU n i v e r s i t y ,K i n g s t o n ,O ntario. Abstracts were
initially obtained using keywords of “smoking cessation”
AND “varenicline. They were further narrowed down by
imposing keywords of “human” AND “controlled trial”.
Manual searches of references and review articles sup-
plemented the computerized search.
Study selection, data extraction and quality assessment
Two reviewers (LL and FP) worked independently and
went over the initial search for abstracts that satisfied the
keywords as mentioned in the search strategy section.
They then adopted a simple form to select trials that
satisfied the eligibility criteria stated above. Evaluation of
selected studies were performed independently by each
reviewer according to the Cochrane risks of bias tool [12]
in regards to the quality of study, randomization proto-
col, adequacy of concealment and blinding and, rigor of
follow-up for dropouts. Information was extracted and
tabulated in spreadsheet regarding the demography of
the study population, duration of study, the types of
adverse events, the number of affected subjects taking
varenicline and placebo respectively and finally a numeric
score for the Cochrane risk of bias. Spreadsheets were
compared and any disagreement was discussed and
resolved to reach mutual consensus.
Statistical Analysis
All data were synthesized in a meta-analysis and odds
ratios (OR) were calculated with appropriate confidence
intervals (CI) basing on the number of subjects report-
ing the relevant adverse effects in the study. Where
necessary, the value of 1 was added to any arm with
zero outcome event according to the Sheele +1 rule
[13]. The random effects analysis model as described by
DerSimonian and Laird [14] was adopted instead of the
fixed effects model to account for extra variance due to
heterogeneous samples drawn from a wide population
[15]. Forest plots [16] were generated basing on OR for
each gastrointestinal symptom of nausea, constipation
and flatulence. Basing on the values of OR and the base-
line risks of adverse effects, the number needed to harm
(NNH) was also calculated which gives a realistic idea of
the likelihood of the adverse effects. Funnel plots [17]
were displayed as a reference for possible publication
bias. To assess heterogeneity across included studies, we
adopted the Cochran Q-statistic [18] and the I
2 index
[19,20] with 95% confidence intervals. We assumed a p-
value of less than 0.10 for the Cochran Q-statistic and
an I
2 index of greater than 50% as a threshold of hetero-
geneity. Statistical advice was provided by data analyst at
our Centre of Studies in Primary Care.
Results
Study description
1431 abstracts were identified using keywords of “smok-
ing cessation” AND “varenicline”, which were reduced
to 108 abstracts when imposing extra keywords of
“human” AND “controlled trial” with supplementation
from reference lists of included abstracts. 10 duplicates
were removed and 82 abstracts were further excluded
on grounds of having no placebo control group, com-
bined mixed treatments, no relevant gastrointestinal
adverse events data, or duplication trial publication or
report. 16 relevant full text paper publications were then
retrieved for potential inclusion. After imposing the elig-
ibility criteria as described, only 12 studies were deemed
eligible upon which mutual consensus was reached
between the reviewers after discussion and comparison
of the data spreadsheets. Using the 2009 PRISMA
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sent and identified scored. A flow diagram of the litera-
ture search and selection process according to the
PRISMA format [21] was given in Figure 1, and the
included studies were tabulated in Table 1. From the 12
studies, 2,622 patients were randomly assigned to
receive varenicline (oral dose of 1 mg twice per day),
and 2,492 patients were randomly assigned to receive
placebo. Total sample size per study ranged from 248 to
714 and three studies had a total size of greater than
500. Except for the study by Tashkin et al. [22] which
specifically targeted patients with COPD, all other stu-
dies recruited subjects from the general population. One
trial used varenicline for 6 weeks [23] while another for
52 weeks [24], the rest used 12 weeks. All but one study
[23] employed the standard low-dose titration regime
b e f o r eu s i n gt h e1m gt w i c ep e rd a yd o s a g e .T h e r ew a s
no exclusion as for the type of tobacco used by smokers
in all trials except for the study by Fagerstrom et al. [9]
which recruited subjects using smokeless tobacco.
Assessment of study quality
All 12 studies achieved a score of at least 4 out of 6, using
the Cochrane risk of bias assessment [12] (See table 1)
and was considered satisfactory with mutual agreement
between the two reviewers. After consultation with our
Figure 1 Flow diagram (in PRISMA format) of literature search.
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subsequent analysis.
Outcome Measures
Nausea
All 12 studies [9,22-32] reported adverse effects of nausea
with a total sample size of 5114. Out of the total 2622
subjects randomized to varenicline, 826 reported nausea;
of the 2492 subjects taking placebo, 232 had nausea. The
pooled OR was 4.45 (95% confidence levels [CI] of 3.79-
5.23, p < 0.001) with a non-significant Cochrane Q-statis-
tic of 11.01 (p =0 . 4 4 3 )a n da nI
2 index of 0.06% (95%
confidence levels of 0% - 58.34%). With a baseline risk of
nausea at 9.3%, the number need to harm (NNH) is 5.
The Forest plot was shown in Figure 2 and funnel plot in
Additional File 2.
Constipation
8 studies [23-30] reported adverse effects of constipation
with a total sample size of 3539. 146 of 1839 subjects in
the varenicline group and 53 of 1700 in the control group
reported adverse effects of constipation. The pooled OR
was 2.45 (95% confidence levels [CI] of 1.61-3.72, p <
0.001) with a non-significant Cochrane Q-statistic of 10.62
(p = 0.156) and an I
2 index of 34.09% (95% confidence
levels of 0% - 70.81%). The baseline risk of constipation is
3.1%, yielding a NNH of 24. The Forest plot was shown in
Figure 3 and the funnel plot in Additional File 2.
Flatulence
5 studies [22,24,25,27,30] were included reporting
adverse effects of flatulence with a total sample size of
2516 subjects. 102 of 1325 subjects in the varenicline
group and 50 of 1191 in the control group reported
adverse effects of flatulence. The pooled OR was 1.74
(95% confidence levels [CI] of 1.23-2.48, p = 0.002) with
a non-significant Cochrane Q-statistic of 1.82 (p =
0.768) and an I
2 index of 0% (95% confidence levels of
0% - 79.2%). With a baseline risk of flatulence at 4.2%,
the NNH is 35. The Forest plot was shown in Figure 4
and the funnel plot in Additional File 2.
Discussion
Our meta-analysis data confirms that using varenicline
at maintenance dose of 1 mg twice per day for a period
of more than 6 weeks is significantly associated with
Table 1 Summary of the 12 studies included for meta-analysis
Study Total
Sample Size
(n)
Adverse
effects
¥
Mean
Age
%
Male
Trial Duration with 1 mg
BID dose(Weeks)
Size of
Trial group
Size of
Control
Group
Cochrane risk of bias
assessment
§
P Q R S T U Overall
score
Gonzales et al
(2006)
32
696 A, B, C 42.55 52.05 12 352 344 1 1 1 1 1 1 6/6
Jorenby et al
(2006)
29
685 A, B, C 43.45 56.65 12 344 341 1 1 1 1 1 0 5/6
Oncken et al
(2006)
27
259 A, B, C 41.1 50.2 12 130 129 1 1 1 1 0 0 4/6
Nides et al
(2006)
25
248 A, B 41.7 51.2 6 125 123 1 1 0 1 1 0 4/6
Nakamura et
al(2007)
30
310 A, B 40 77.6 12 156 154 1 1 1 1 1 1 6/6
Tsai et al
(2007)
28
250 A, B 40.3 88.8 12 126 124 1 1 0 1 1 0 4/6
Williams et al
(2007)
26
377 A, B, C 47.7 48.6 52 251 126 1 1 0 1 1 0 4/6
Niaura et al
(2008)
34
312 A 41.8 51.9 12 157 155 1 1 1 1 1 0 5/6
Wang et al
(2009)
33
333 A 38.7 96.7 12 165 168 1 1 0 1 1 0 4/6
Rigotti et al
(2010)
31
714 A, B 56.45 78.7 12 355 359 1 1 0 1 1 1 5/6
Fagerstrom et
al(2010)
8
431 A 43.9 89.3 12 213 218 1 1 1 1 1 1 6/6
Tashkin et al
(2010)
24
499 A, C 57.2 62.3 12 248 251 1 1 0 1 1 0 4/6
¥A = Nausea, B = Constipation, C-Flatulence.
#Denote use of 1-week low-dose titration treatment.
§Cochrane risk of bias assessment: P = Allocation sequence adequately generated?; Q = Allocation adequately concealed?; R = Knowledge of allocated
intervention adequately concealed?; S = incomplete outcome data adequately addressed?; T = Reports free of selective outcome reporting?; U = study free of
other factors leading to high risk of bias?; 1 = item positive; 0 = negative or unknown.
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Figure 3 Forest plot showing odds ratio for constipation.
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pation and flatulence. Using pooled odds ratios (OR)
and subsequently translating them to number need to
harm (NNH), we showed that for nausea, constipation
and flatulence, the NNH is 5, 24 and 35 respectively.
Such numbers provide clinicians with a realistic picture
of the likelihood for gastrointestinal adverse effects
when prescribing varenicline as a drug of choice for
smoking cessation. As the commonest gastrointestinal
adverse effect, nausea accounts for failure of varenicline
treatment amongst 1.8% to 7.6% of our study population
[24,26,27,30,31]. The effects of nausea usually peak
around 4 weeks of treatment and becoming less there-
after [24]. No similar discontinuation rates due to effects
of constipation or flatulence have been reported.
Limitation of studies
Our study has two limitations. Gastrointestinal adverse
effects like nausea and flatulence are primarily subjective
feelings which are difficult to quantify, despite crude stra-
tification into mild, moderate or severe in several studies.
Definition for constipation is also not standardised as per
Rome criteria [33] amongst the included studies in terms
of bowel frequency or patient’s difficulty in defecation.
They may constitute data heterogeneity across studies in
our meta-analysis.
The second limitation is the potential of publication
bias. Our search strategy only isolated full-length pub-
lished trials with sufficient population sizes to maintain
statistical significance. In addition, we excluded studies
with populations less than 40. However adoption of the
random effects model in meta-analysis will help compen-
sate irregularities due to small and potentially negative
studies that we have excluded. Our funnel plots do not
show obvious asymmetry (Additional File 2), suggesting
the low likelihood of publication bias in our analysis.
Thus said, the visual asymmetry of funnel plots should
not be used to confirm the extent of publication bias
[34], especially when the number of studies is small [35].
The I
2 index suggests very low heterogeneity across stu-
dies for both nausea and flatulence (both at 0%) and
slightly higher but still acceptable heterogeneity for con-
stipation (34%)[20]. Like the Cochran Q-statistic, the I
2
index is known to have limitations with its power affected
by the actual number of included studies [36].
Conclusions
Varenicline is one of the most preferred pharmacological
options for smoking cessation and gastrointestinal
adverse effects have been mentioned but not documented
precisely. Our comprehensive meta-analysis on rando-
mised double-blind placebo-controlled trials concluded
Figure 4 Forest plot showing odds ratio for flatulence.
Leung et al. BMC Clinical Pharmacology 2011, 11:15
http://www.biomedcentral.com/1472-6904/11/15
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maintenance dose (1 mg twice per day) for longer than 6
weeks will lead to one adverse event of nausea for every 5
treated subjects, one event of constipation for every trea-
ted 24 subjects and one event of flatulence for every 35
treated subjects. These data will better enable clinicians
in counseling patients when using varenicline for smok-
ing cessation both in facilitating and reinforcing optimal
smoking cessation rate.
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